Mar 26, 2019
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
Mar 20, 2019
Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
Mar 17, 2019
Immutep to Present IMP761 Preclinical Results in Global Webcast
Mar 06, 2019
Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
Immutep doses First Patient in TACTI-002 Phase II Trial
Mar 05, 2019
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
Mar 03, 2019
Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
Feb 26, 2019
Immutep to Present at Upcoming Industry Conferences
Jan 07, 2019
Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic
Dec 19, 2018
Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital
Nov 27, 2018
New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit
Nov 11, 2018
Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
